Alchemab to Collaborate With AstraZeneca to Use Alchemab’s Drug Discovery Platform for Prostate Cancer Study
Proof-of-concept immuno-oncology collaboration with
to build understanding of prostate cancer AstraZeneca
- Alchemab’s advanced analytics to be used to analyse patient immune responses, identify natural mechanisms of protection and novel drug targets, and predict patient responsiveness
- Collaboration may lead to identification of novel therapeutics and disease biomarkers for prostate cancer, and may inform a diagnostics approach for patient stratification
Using cutting-edge advanced analytics and functional validation methods, Alchemab will sequence and explore antibody repertoires within patient samples from a clinical trial of a novel immuno-oncology agent in the
By classifying patients as responders or non-responders, Alchemab may also be able to identify antibody sequence patterns that could function as biomarkers for early detection and patient stratification, enabling researchers to predict and monitor responses to novel immuno-oncology agents.
Prostate cancer is the second most frequent cancer diagnosis made in men, and the fifth leading cause of death worldwide1. It accounts for 1.4 million, or 7.3% of all new cancer cases every year globally2.
Alchemab recently announced that it had raised £60 million (
- Ends -
Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics on the basis of patient antibody repertoires. The platform uses well-defined patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody responses in individuals that are susceptible but resilient to specific diseases.
Alchemab is building a broad pipeline of protective therapeutics for hard-to-treat diseases, with an initial focus on oncology, neurodegenerative conditions and infectious diseases.
Alchemab was founded in 2019 and brings together expertise from
Alchemab is led by highly experienced management and has an extended team of scientific founders and collaborators. Together, Alchemab’s team and collaborators bring together a wide range of expertise from the fields of oncology, neuroscience, infectious diseases and computational biology.
Alchemab’s R&D facility is in
For more information, visit www.alchemab.com.
Tel: +44 (0) 20 7457 2020